Open AccessComparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer
Author(s) -
Jianxin Chen,
Junhui Wang,
Hui Xu
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000025180
Subject(s) - atezolizumab , durvalumab , medicine , pembrolizumab , nivolumab , oncology , hazard ratio , adverse effect , odds ratio , cancer , confidence interval , immunotherapy